Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
434 questions in 75 reviews · Metabolic and Endocrine Disorders
current versionsNo studies 434 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Health‐related quality of life · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Sexual quality of life · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Prostate‐related events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs placebo Lower urinary tract symptoms · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Treatment withdrawal due to adverse events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone vs PDE5I Lower urinary tract symptoms · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone as an add‐on to PDE5I vs PDE5I alone Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Testosterone as an add‐on to PDE5I vs PDE5I alone Lower urinary tract symptoms · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Disease‐related complications · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs preoperative pharmacological therapy and surgery All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs preoperative pharmacological therapy and surgery Health‐related quality of life · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Disease recurrence · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Surgery for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgery alone vs pharmacological therapy alone Non‐surgical therapy for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting… (2024) · Cochrane | no estimate extracted | NR | No studies |
Low glycaemic index (GI) or low glycaemic load (GL) diets vs any other diet All‐cause mortality · people with obesity or overweight Low glycaemic index or low glycaemic load diets for people with overweight or obesity (2023) · Cochrane | no estimate extracted | NR | No studies |
Low glycaemic index (GI) or glycaemic load (GL) diets vs higher GI or GL diets All‐cause mortality · people with overweight or obesity Low glycaemic index or low glycaemic load diets for people with overweight or obesity (2023) · Cochrane | no estimate extracted | NR | No studies |
Low glycaemic index (GI) or low glycaemic load (GL) diets vs any other diet Health‐related quality of life · people with obesity or overweight Low glycaemic index or low glycaemic load diets for people with overweight or obesity (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas Adverse events other than hypoglycaemia Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
SGLT‐2 inhibitors vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
SGLT‐2 inhibitors vs sulphonylureas All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
SGLT‐2 inhibitors vs sulphonylureas Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
DPP‐4 inhibitors vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
GLP‐1 analogues inhibitors vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
GLP‐1 analogues inhibitors vs sulphonylureas All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Insulin analogues vs biphasic insulin Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Insulin analogues vs biphasic insulin Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Telemedicine vs usual care Adverse events other than hypoglycaemia Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Telemedicine vs usual care All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Telemedicine vs usual care Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care Adverse events other than hypoglycaemia Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Patient education vs usual care Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care All‐cause mortality Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Drug dosage reduction vs usual care HbA1c (%) Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
DPP‐4 inhibitors vs sulphonylureas Treatment satisfaction Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
DPP‐4 inhibitors vs sulphonylureas Self‐care Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Meglitinides vs sulphonylureas Health‐related quality of life Interventions for people with type 2 diabetes mellitus fasting during Ramadan (2023) · Cochrane | no estimate extracted | NR | No studies |
Obesity Class I vs Normal Weight or Non‐Obese OutcomesTime frame of absolute effects · Adults with COVID‐19 Obesity as an independent risk factor for COVID‐19 severity and mortality (2023) · Cochrane | no estimate extracted | NR | No studies |
Obesity Class II vs Normal Weight or Non‐Obese Severe COVID · Adults with COVID‐19 Obesity as an independent risk factor for COVID‐19 severity and mortality (2023) · Cochrane | no estimate extracted | NR | No studies |
Obesity Class II vs Normal Weight or Non‐Obese Pneumonia · Adults with COVID‐19 Obesity as an independent risk factor for COVID‐19 severity and mortality (2023) · Cochrane | no estimate extracted | NR | No studies |